The FDA advisory committee voted 9-3 that current evidence does not support the effectiveness of Capricor Therapeutics' Deramiocel for treating cardiomyopathy in Duchenne muscular dystrophy (DMD) patients. However, the vote was non-binding and focused on a narrower indication than Capricor proposed. The committee showed some support for Deramiocel's benefits on upper limb function based on Phase 3 trial data. Capricor remains committed to pursuing FDA approval by the August 22, 2026 target date, emphasizing the unmet medical need in DMD, a severe genetic disease with no approved cardiomyopathy treatments.
Sanofi has published its half-year financial report for the period ending June 30, 2026, available on its website and filed with regulatory authorities in France and the US. The report highlights Sanofi's strong business performance, including double...
Sanofi has published its financial report for the first half of 2026, available on its website and filed with the French financial authority (AMF). The biopharmaceutical company highlights its innovation in R&D and use of AI to drive long-term growth...
Frank Patton and Kimberlee Mott, financial advisors with 45 years of combined experience managing about $150 million in assets, have joined Balmville Wealth Group through LPL Financial. They bring a focus on retirement planning and multigenerational ...
Crescent Biopharma announced its second quarter 2026 financial results, highlighting progress in clinical trials for its cancer therapies, including CR-001, a PD-1 x VEGF bispecific antibody, and ADC candidates CR-002 and CR-003. The company is enrol...
Ferrari reported Q2 2026 net revenues of €1.94 billion, up 8% year-on-year, driven by a richer product mix and increased personalization sales. Operating profit rose 10% to €605 million with a margin of 31.2%, while net profit grew 9% to €463 million...
